HomeICPT • BMV
Intercept Pharmaceuticals Ord Shs
$0.00
Mar 15, 2:23:33 PM GMT-6 · MXN · BMV · Disclaimer
StockMX listed security
Previous close
$329.00
Year range
$329.00 - $329.00
Market cap
794.36M USD
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2023Y/Y change
Revenue
88.79M14.44%
Operating expense
86.95M-0.41%
Net income
-2.79M-101.04%
Net profit margin
-3.14-100.91%
Earnings per share
0.08-99.20%
EBITDA
1.74M117.27%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2023Y/Y change
Cash and short-term investments
322.71M-34.25%
Total assets
393.16M-29.72%
Total liabilities
321.32M-28.87%
Total equity
71.84M
Shares outstanding
41.83M
Price to book
191.28
Return on assets
0.93%
Return on capital
1.18%
Net change in cash
(USD)Sep 2023Y/Y change
Net income
-2.79M-101.04%
Cash from operations
16.69M200.59%
Cash from investing
59.77M-81.97%
Cash from financing
-110.00M57.27%
Net change in cash
-33.70M-163.39%
Free cash flow
16.70M211.23%
About
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
Founded
2002
Employees
341
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu